Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS; International Breast Cancer Study Group. Viale G, et al. Among authors: price kn. J Natl Cancer Inst. 2008 Feb 6;100(3):207-12. doi: 10.1093/jnci/djm289. Epub 2008 Jan 29. J Natl Cancer Inst. 2008. PMID: 18230798 Free article.
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG); Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M, Gelber RD. International Breast Cancer Study Group (IBCSG), et al. Among authors: price kn. J Natl Cancer Inst. 2003 Dec 17;95(24):1833-46. doi: 10.1093/jnci/djg119. J Natl Cancer Inst. 2003. PMID: 14679153 Clinical Trial.
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
International Breast Cancer Study Group; Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD. International Breast Cancer Study Group, et al. Among authors: price kn. J Clin Oncol. 2006 Mar 20;24(9):1332-41. doi: 10.1200/JCO.2005.03.0783. Epub 2006 Feb 27. J Clin Oncol. 2006. PMID: 16505417 Clinical Trial.
Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurküla M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B; International Breast Cancer Study Group. Regan MM, et al. Among authors: price kn. J Natl Cancer Inst. 2006 Nov 1;98(21):1571-81. doi: 10.1093/jnci/djj415. J Natl Cancer Inst. 2006. PMID: 17077359 Free article.
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.
International Breast Cancer Study Group; Colleoni M, Gelber S, Simoncini E, Pagani O, Gelber RD, Price KN, Castiglione-Gertsch M, Coates AS, Goldhirsch A. International Breast Cancer Study Group, et al. Among authors: price kn. Ann Oncol. 2007 Jul;18(7):1177-84. doi: 10.1093/annonc/mdm091. Epub 2007 Apr 11. Ann Oncol. 2007. PMID: 17429101 Free article. Clinical Trial.
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Viale G, et al. Among authors: price kn. J Clin Oncol. 2007 Sep 1;25(25):3846-52. doi: 10.1200/JCO.2007.11.9453. Epub 2007 Aug 6. J Clin Oncol. 2007. PMID: 17679725 Clinical Trial.
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Viale G, et al. Among authors: price kn. J Clin Oncol. 2008 Mar 20;26(9):1404-10. doi: 10.1200/JCO.2007.10.6393. J Clin Oncol. 2008. PMID: 18349391 Clinical Trial.
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98. Viale G, et al. Among authors: price kn. J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3. J Clin Oncol. 2008. PMID: 18981464 Free PMC article. Clinical Trial.
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.
Maiorano E, Regan MM, Viale G, Mastropasqua MG, Colleoni M, Castiglione-Gertsch M, Price KN, Gelber RD, Goldhirsch A, Coates AS. Maiorano E, et al. Among authors: price kn. Breast Cancer Res Treat. 2010 May;121(1):211-8. doi: 10.1007/s10549-009-0360-y. Epub 2009 Mar 12. Breast Cancer Res Treat. 2010. PMID: 19280340 Free PMC article. Clinical Trial.
155 results